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Abstract
Background: The evidence on the use of the oral dimethyl-fumarate after the discontinuation of treatment with
natalizumab in people with Multiple Sclerosis is still little. Natalizumab discontinuation may induce the recurrence
or rebound of the clinical and neuroradiological disease activity. Currently no therapeutic approach has been established
to abolish disease reactivation and rebound after natalizumab interruption.
Case Presentation: We describe a case of a 21-year-old woman affected from a highly active relapsing-remitting
Multiple Sclerosis who developed a clinical and radiological rebound 5 months after the last infusion of natalizumab,
while she was being treated with dimethyl-fumarate 240 mg twice daily. She had received a bridge “therapy”
with Cyclophosphamide before staring dimethyl-fumarate.
Conclusion: We report on this case to stimulate further research to establish whether new current and future
drugs available for multiple sclerosis are able to halt the disease rebound after the natalizumab interruption.
Keywords: Multiple sclerosis, Natalizumab discontinuation, Dimethyl-fumarate, Clinical rebound, Radiologic
activity, Switching therapy
Background
Natalizumab (NAT), a specific a4-integrin antagonist block-
ing lymphocytes transmigration across the blood–brain
barrier, is a second-line treatment of active relapsing-
remitting (RR) multiple sclerosis (MS). The benefit of re-
duction in relapse rate, disability progression and Magnetic
Resonance Imaging (MRI) lesions load has to be weighed
against the risks of adverse events [1]. Which is mainly re-
lated to the rare but serious progressive multifocal leukoen-
cephalopathy (PML); longer treatment duration increases
the risk of this adverse event [2, 3]. After NAT discontinu-
ation, MRI and clinical disease activity gradually return to
the pre-treatment levels [2], sometimes even a rebound
with a flare-up to a level beyond the pre-NAT treatment
level was reported [4–6]. There are no available random-
ized controlled trials or established guidelines on “what to
do after NAT therapy”. The RESTORE study showed that
disease activity began 12-weeks after NAT-discontinuation
and occurred regardless of following “drug holiday”,
“bridge” therapy or “switch” to an alternative treatment
with either glatimarer acetate or interferons [7]. On the
contrary, those who continued NAT did not show MRI evi-
dence of new disease activity, suggesting that only NAT can
stop the rebound due to NAT-interruption. However, in
that study [7], new switching options which are available ei-
ther currently or in the near future, such as fingolimod,
dimethyl-fumarate (DMF), teriflunomide and alemtuzumab
were not included. Furthermore, other observational stud-
ies were conducted to investigate the effect of fingolimod in
preventing disease reactivation after NAT discontinuation
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[8–12]. Among them, five studies showed clearly that early
initiation of fingolimod (less than 2 or 3 months after dis-
continuing NAT) decreases the probability of disease re-
activation [8, 10–13], highlighting the importance of an
early treatment after NAT withdrawal. Iaffaldano et al.
showed a superiority of fingolimod in comparison to inter-
feron beta/glatiramer acetate in controlling disease reactiva-
tion after NAT discontinuation in a large sample of real life
setting [13]. Preliminary evidences showed both positive
[14, 15], and negative effect of DMF on minimizing disease
activity in persons with MS switching from NAT [16].
To summarize, data about MS rebound occurrences in
patients treated with DMF after NAT-discontinuation are
not available in literature.
Case presentation
We report the case of a 21-year-old woman who in August
2011 was diagnosed with RRMS. She had no previous rele-
vant medical conditions, nor family history of immune dis-
eases. The disease onset was on May 2011 with acute
cerebellar-related balance problems and spontaneously re-
covered after 3 weeks (EDSS 1.5). Shortly after the diagno-
sis, in October 2011, she was enrolled in the DECIDE
study (double blind randomized controlled trial with IFN-
beta 1a and Daclizumab 150 mg (DAC-HYP). However,
she withdrew at early stages from this study (July 2012)
due to the occurrence of two MS-relapses, both character-
ized by bi-ocular diplopia and blurred vision (EDSS 3.0).
She completely recovered from this relapse after high dose
of i.v. steroids. An MRI scan performed on May 2012
showed important radiological disease activity in the brain
(25 T2-weighted and 7 T1-weighted/gadolinium-enhanced
lesions) as well as in the spine (9 T2-weitghed and 2 T1-
weighted/gadolinium-enhanced lesions). In August 2012,
she started i.v. NAT 300 mg every 28 days. She was sero-
positive for JC-virus antibody status. During the 2 years of
NAT-treatment, she was free of clinical activity and had a
stable disability level (EDSS 1.5). She also underwent serial
brain and spine MRI scans every 6 months, which showed
no radiological disease activity as shown in Fig. 1. However,
after 24 NAT-infusions (August 2014), administration of
NAT was interrupted due to the risk of PML.
A single pulse of i.v. cyclophosphamide 750 mg was ad-
ministered in September 2014. Following this, in October
2014 she was switched to DMF, starting with 120 mg
twice-a-day for the first 2 weeks, and then switching to
DMF 240 mg twice-a-day. Shortly, after the change of dos-
age, she started to complain of adverse effects in the region
of gastro-intestine, which was mainly characterized by nau-
sea and weight-loss – by January 2015, she lost 15 kg. On
15/01/2015, she started to complain of new symptoms
characterized by lower limb weakness, dizziness and gait
ataxia, followed by bilateral blurred vision, in the absence of
fever and other infection signs. When she arrived to our
clinic, the neurological examination revealed an EDSS of
6.0 since the patient was able to walk only with a unilateral
support for about 100 m. A new brain MRI showed massive
progression in T2 lesions and lesions with ring gadolinium-
enhancement numbers (>20 gadolinium-enhanced lesions,
Fig. 2). A 5-day steroid course was then administered intra-
venously with great clinical benefit. The MRI performed
1 month later showed a reduction of the number of
gadolinium-enhanced lesions in the brain. After one add-
itional month, she recovered completely from the relapse
and the neurological examination showed an EDSS of 1.5.
On 24/02/2015 she re-started the treatment with NAT.
The new JC-virus antibody status index was three.
The young MS patient reported in this case had a
severe clinical and radiological rebound after NAT-
interruption, although she was being treated with DMF,
which in turn was started as after a “bridge” therapy
with cyclophosphamide.
DMF, an oral treatment for RRMS with immunomo-
dulatory and cytoprotective effects [17], was not able to
stop the clinical and MRI activity after NAT-interruption.
Recent preliminary results on the effect of DMF on min-
imizing disease activity related to NAT-interruption have
been reported with inconclusive results. Two studies
reported on beneficial effects [14, 15], and one showed
higher disease activity (frequency of patients with relapse)
during DMF treatment period compared with NAT period
treatment [16]. However, no rebound activity of MS has
been shown so far. The AFFIRM, SENTINEL and
GLANCE studies showed no rebound [2], but the
RESTORE reported a high rate of disease activity after
NAT-interruption despite a new drug was started [7].
Since this study proved the superiority of continuing NAT
Fig. 1 Axial (a) T2-weighted FLAIR MRI under stable clinical conditions,
showing several supratentorial lesions; axial (b) T1-weighted images
showing no lesions with ring gadolinium-enhancement, (c) sagittal
T2-weighted FLAIR MRI showing two spinal cord lesions
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in comparison with its interruption despite switching to
first-line disease modifying drugs or methylprednisolone,
we decided to restart therapy with NAT. Despite her risk
of PML, which was likely higher due to the single pulse of
immunosuppressant we administered as a bridge therapy.
We however started an accurate and strict monitoring of
clinical and radiological activity including MRI scans every
3–4 months.
Yet, the best treatment of patients who withdraw from
NAT independently from the interruption reasons does not
exist. Several strategies applied in clinical practice, such as
“bridge” therapy with methylprednisolone, switching to gla-
timarer acetate or interferon-beta are likely not effective
[18]. However, more promising results came from several
small [8, 10] and large retrospective [11, 12] and prospective
[13] studies with fingolimod (FTY), but long-term data
about its efficacy and safety after NAT are urgently needed.
Finally we cannot exclude that the single pulse of cyclophos-
phamide we used as “bridge” therapy to DMF might have
delayed the occurrence of a rebound of another 3 months.
Conclusions
To summarize, this is the first case of MS rebound after
switching from NAT to DMF, independently from the sin-
gle pulse of cyclophosphamide. Yet, the best therapeutic ap-
proach to abolish the disease reactivation after the NAT-
discontinuation needs to be found. Considering the narrow
time window for the diminishing clinical and biological ef-
fects of NAT, we suggest to investigate in depth whether
starting the new MS therapy together with the NAT (dur-
ing i.e. the last three months of the NAT treatment) may be
effective.
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